Redmile Group, LLC — 13F Holdings & Portfolio
CIK 1425738 · latest 13F-HR filed 2026-08-14
Redmile Group, LLC manages $1.49B in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are SRRK (15.92%), KRYS (15.77%), STOK (8.67%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions and exited 0; 18 existing positions rose in reported value and 14 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 73.5%Cumulative share of the portfolio held in the largest N positions.
BLDG D, STE D3-300
SAN FRANCISCO, CA 94129
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| Breznak, Travis, John Control | CHIEF FINANCIAL OFFICER | Less than 5% | Individual |
| CRAPO, BRYAN, RANNEY Control | CHIEF OPERATING OFFICER | 5–10% | Individual |
| GARCIA, JOSHUA, DAMIAN Control | CHIEF COMPLIANCE OFFICER | Less than 5% | Individual |
| GREEN, JEREMY, CHARLES Control | MANAGING MEMBER | 50–75% | Individual |
| LEE, MICHAEL, STEWART Control | MANAGING DIRECTOR | 10–25% | Individual |
| FAULKNER, ROBERT, CARRINGTON | MANAGING DIRECTOR | 5–10% | Individual |
| NAGPAL, AMRIT, NMN | MANAGING DIRECTOR | Less than 5% | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- KRYSTAL BIOTECH INC$60.9M +35.0%
- ABSCI CORPORATION$53.4M +215.5%
- AGOMAB THERAPEUTICS NV$33.8M +2065.0%
- FATE THERAPEUTICS INC$19.3M +125.0%
- REGENXBIO INC$15.7M +43.0%
Top Trims
- SCHOLAR ROCK HLDG CORP-$208.6M -46.8%
- ADC THERAPEUTICS SA-$45.7M -78.7%
- NURIX THERAPEUTICS INC-$21.0M -17.5%
- IMMUNOME INC-$17.5M -14.4%
- ANNEXON INC-$12.8M -15.9%
New Positions
- CLIMB BIO INC$16.0M
- AURA BIOSCIENCES INC$11.8M
- ODYSSEY THERAPEUTICS INC$8.0M
- INSMED INC$5.5M
Redmile Group, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $237.1M | 15.92% | 4,311,092 | SH |
| 2 | KRYSTAL BIOTECH INC | KRYS | 501147102 | $234.9M | 15.77% | 632,005 | SH |
| 3 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $129.1M | 8.67% | 3,945,920 | SH |
| 4 | IMMUNOME INC | IMNM | 45257U108 | $104.1M | 6.99% | 4,911,590 | SH |
| 5 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $98.8M | 6.64% | 4,073,787 | SH |
| 6 | ABSCI CORPORATION | ABSI | 00091E109 | $78.1M | 5.24% | 6,739,675 | SH |
| 7 | ANNEXON INC | ANNX | 03589W102 | $67.8M | 4.55% | 11,869,877 | SH |
| 8 | REGENXBIO INC | RGNX | 75901B107 | $52.3M | 3.51% | 4,368,804 | SH |
| 9 | SHATTUCK LABS INC | STTK | 82024L103 | $47.8M | 3.21% | 6,892,033 | SH |
| 10 | NEUROGENE INC | NGNE | 64135M105 | $44.4M | 2.98% | 1,412,199 | SH |
| 11 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $40.0M | 2.68% | 1,164,259 | SH |
| 12 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $35.5M | 2.38% | 2,733,926 | SH |
| 13 | FATE THERAPEUTICS INC | FATE | 31189P102 | $34.8M | 2.33% | 12,872,946 | SH |
| 14 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $23.9M | 1.60% | 640,202 | SH |
| 15 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $23.8M | 1.60% | 2,164,777 | SH |
| 16 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $19.5M | 1.31% | 503,321 | SH |
| 17 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $19.5M | 1.31% | 1,948,695 | SH |
| 18 | NUVATION BIO INC | NUVB | 67080N101 | $17.2M | 1.16% | 3,031,009 | SH |
| 19 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $16.1M | 1.08% | 433,921 | SH |
| 20 | CLIMB BIO INC | CLYM | 28658R106 | $16.0M | 1.07% | 1,226,330 | SH |
| 21 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $15.3M | 1.03% | 7,392,504 | SH |
| 22 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $15.2M | 1.02% | 265,169 | SH |
| 23 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $13.8M | 0.93% | 229,374 | SH |
| 24 | ZYMEWORKS INC | ZYME | 98985Y108 | $12.9M | 0.86% | 491,654 | SH |
| 25 | ADC THERAPEUTICS SA | ADCT | H0036K147 | $12.3M | 0.83% | 11,526,710 | SH |
| 26 | AURA BIOSCIENCES INC | AURA | 05153U107 | $11.8M | 0.79% | 1,666,667 | SH |
| 27 | ODYSSEY THERAPEUTICS INC | ODTX | 67613T104 | $8.0M | 0.53% | 425,000 | SH |
| 28 | LIVANOVA PLC | LIVN | G5509L101 | $7.7M | 0.51% | 93,154 | SH |
| 29 | ESTABLISHMENT LABS HLDGS INC | ESTA | G31249108 | $7.6M | 0.51% | 88,964 | SH |
| 30 | CERIBELL INC | CBLL | 15678C102 | $7.5M | 0.51% | 386,786 | SH |
| 31 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $6.7M | 0.45% | 410,440 | SH |
| 32 | INSMED INC | INSM | 457669307 | $5.5M | 0.37% | 51,234 | SH |
| 33 | PRIME MEDICINE INC | PRME | 74168J101 | $5.1M | 0.34% | 1,389,632 | SH |
| 34 | ATARA BIOTHERAPEUTICS INC | ATRA | 046513206 | $5.1M | 0.34% | 441,701 | SH |
| 35 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $4.0M | 0.27% | 611,400 | SH |
| 36 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $3.9M | 0.26% | 362,010 | SH |
| 37 | ARDELYX INC | ARDX | 039697107 | $3.3M | 0.22% | 641,750 | SH |
| 38 | INVIVYD INC | IVVD | 00534A102 | $2.3M | 0.15% | 2,597,759 | SH |
| 39 | PLIANT THERAPEUTICS INC | PLRX | 729139105 | $880.2K | 0.06% | 772,126 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.49B | 39 | 0001104659-26-097182 |
| 2026-03-31 | 2026-05-15 | $1.51B | 35 | 0001104659-26-062579 |
| 2025-12-31 | 2026-02-17 | $1.36B | 34 | 0001104659-26-016433 |
| 2025-09-30 | 2025-11-14 | $1.03B | 40 | 0001104659-25-112572 |
SUITE 270
LARKSPUR, CA 94939